Home

Browse

Statistics

Number of samples

Name	Count
PDX	63
Tumour Sample	45
Patient	37

Host Type

Host type	Count
Testosterone supplemented	41
Castrate	18

Graft Site

Graft site	Count
Subcutaneous	51
Renal	8

Treatment prior to specimen collection

Treatment type	Count
ADT	21
Docetaxel	18
None	15
Cabazitaxel	12
Enzalutamide	12
Abiraterone	10
Zoladex	5
Radiotherapy	5
Carboplatin plus etoposide	5
Niraparib	4
PRRT LuTate and Y-Tate	2
Octreotide	2
Ketoconazole	1
Prednisolone	1
Zoledronate	1
Lutetium psma	1
Pembrolizumab	1
Navelbine	1
Zoladex and cosudex	1

Sample site of clinical sample

Treatment type	Count
PROSTATE	13
Brain	7
LIVER	6
DURA	4
Lymph node	3
SPINE	2
LUNG	2
SUPRAPUBIC MASS	1
RIGHT LUNG SUB PLEURAL TUMOUR	1
SMALL BOWEL SEROSA	1
TUMOUR UNDER DIAPHRAGM	1
PERITONEAL NODULE NEAR COLON	1
TUMOUR ADJACENT TO PANCREAS	1
LEFT ILIUM	1

Sample source

Pathology Tumor Diagnosis

Latest News

The future of patient-derived xenografts in prostate cancer research. Nature Reviews Urology, 2023 [Read Here]

The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nature Communications, 2021 [Read Here]

Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer. Journal of Pathology, 2021 [Read Here]

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. European Urology, 2018 [Read Here]